Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC001 (EpCAM CAR-T) in Advanced Digestive System Malignancies
NCT05028933Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Sep 2021
- Primary completion
- Dec 2024
- Modality
- CAR-T Cells, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous CAR-T cell injection targeting EpCAM in hepatocellular carcinoma (HCC), colorectal cancer (CRC), gastric cancer (GC) and 1 more (2 arms), sponsored by Zhejiang University. Primary endpoints: Dose Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Sep 2021; status: recruiting.
02
Drugs
autologous CAR-T cell injection targeting EpCAM
03
Conditions
hepatocellular carcinoma (HCC)colorectal cancer (CRC)gastric cancer (GC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05028933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05028933.